An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/darunavir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms LAPTOP
- 13 Mar 2019 Planned End Date changed from 1 Jul 2022 to 1 Dec 2021.
- 13 Mar 2019 Planned primary completion date changed from 1 Jan 2022 to 1 Jun 2021.
- 13 Mar 2019 Status changed from not yet recruiting to recruiting.